New York Life Investment Management LLC Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New York Life Investment Management LLC lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,532 shares of the biotechnology company’s stock after selling 574 shares during the period. New York Life Investment Management LLC’s holdings in Sarepta Therapeutics were worth $1,159,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Manchester Capital Management LLC increased its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank increased its holdings in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics during the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.52.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Trading Down 5.2 %

Shares of Sarepta Therapeutics stock opened at $101.22 on Tuesday. Sarepta Therapeutics, Inc. has a 1 year low of $100.14 and a 1 year high of $173.25. The firm has a market cap of $9.67 billion, a PE ratio of 80.98 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a 50 day simple moving average of $115.51 and a two-hundred day simple moving average of $122.23.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.